Minimizing the risk of hypoglycemia with vildagliptin: Clinical experience, mechanistic basis, and importance in type 2 diabetes management

by Dejager, Sylvie, Schweizer, Anja
Published 2011

Experience with Vildagliptin in Patients ≥75 Years with Type 2 Diabetes and Moderate or Severe Renal Impairment

by Schweizer, Anja, Dejager, Sylvie
Published 2013

Evidence to support the use of vildagliptin monotherapy in the treatment of type 2 diabetes mellitus

by Dejager, Sylvie, Schweizer, Anja, Foley, James E
Published 2012

Impact of Insulin Resistance, Body Mass Index, Disease Duration, and Duration of Metformin Use on the Efficacy of Vildagliptin

by Schweizer, Anja, Dejager, Sylvie, Foley, James E.
Published 2012

A double-blind, randomized trial, including frequent patient–physician contacts and Ramadan-focused advice, assessing vildagliptin and gliclazide in patients with type 2 diabetes f...

by Hassanein, Mohamed, Abdallah, Khalifa, Schweizer, Anja
Published 2014

Experience with DPP-4 inhibitors in the management of patients with type 2 diabetes fasting during Ramadan

by Schweizer, Anja, Halimi, Serge, Dejager, Sylvie
Published 2013

Blood pressure and fasting lipid changes after 24 weeks’ treatment with vildagliptin: a pooled analysis in >2,000 previously drug-naïve patients with type 2 diabetes mellitus

by Evans, Marc, Schweizer, Anja, Foley, James E
Published 2016

Clinical evidence and mechanistic basis for vildagliptin’s effect in combination with insulin

by Schweizer, Anja, Foley, James E, Kothny, Wolfgang, Ahrén, Bo
Published 2013

Is There Evidence of Any Safety Differences Among DPP-4 Inhibitors in the Treatment of People with Type 2 Diabetes Mellitus and Reduced GFR Due to Chronic Kidney Disease?

by Evans, Marc, Dejager, Sylvie, Schweizer, Anja, Foley, James E.
Published 2015

Changes in body weight after 24 weeks of vildagliptin therapy as a function of fasting glucose levels in patients with type 2 diabetes

by Blüher, Matthias, Schweizer, Anja, Bader, Giovanni, Foley, James E
Published 2014

Efficacy of vildagliptin in combination with insulin in patients with type 2 diabetes and severe renal impairment

by Lukashevich, Valentina, Schweizer, Anja, Foley, James E, Dickinson, Sheila, Groop, Per-Henrik, Kothny, Wolfgang
Published 2013

Comparison of vildagliptin and sitagliptin in patients with type 2 diabetes and severe renal impairment: a randomised clinical trial

by Kothny, Wolfgang, Lukashevich, Valentina, Foley, James E., Rendell, Marc S., Schweizer, Anja
Published 2015

Four-Point Preprandial Self-Monitoring of Blood Glucose for the Assessment of Glycemic Control and Variability in Patients with Type 2 Diabetes Treated with Insulin and Vildaglipti...

by Tura, Andrea, Farngren, Johan, Schweizer, Anja, Foley, James E., Pacini, Giovanni, Ahrén, Bo
Published 2015

Higher Risk of Hypoglycemia with Glimepiride Versus Vildagliptin in Patients with Type 2 Diabetes is not Driven by High Doses of Glimepiride: Divergent Patient Susceptibilities?

by Ahrén, Bo, Foley, James Edward, Dejager, Sylvie, Akacha, Mouna, Shao, Qing, Heimann, Guenter, Dworak, Markus, Schweizer, Anja
Published 2014

Effect of Vildagliptin on Hepatic Steatosis

by Macauley, Mavin, Hollingsworth, Kieren G., Smith, Fiona E., Thelwall, Peter E., Al-Mrabeh, Ahmad, Schweizer, Anja, Foley, James E., Taylor, Roy
Published 2015

International REgistry to assess medical Practice with lOngitudinal obseRvation for Treatment of Heart Failure (REPORT‐HF): rationale for and design of a global registry

by Filippatos, Gerasimos, Khan, Sadiya Sana, Ambrosy, Andrew P., Cleland, John G.F., Collins, Sean P., Lam, Carolyn S.P., Angermann, Christiane E., Ertl, Georg, Dahlström, Ulf, Hu, Dayi, Dickstein, Kenneth, Perrone, Sergio V., Ghadanfar, Mathieu, Bermann, Georgina, Noe, Adele, Schweizer, Anja, Maier, Thomas, Gheorghiade, Mihai
Published 2015